2Zhou X J,Silva F G.Membranoproliferative glomerulonephritis//[M] Jennette J C,Olson J L,Schwartz M M,Silva F G,et al ed.Heptistall's pathology of the kidney.Philadelphia:Lippincott Williams & Willkins,2007:253-319.
3Walker P D.Dense deposit disease:new insights[J].Curr Op in Nephrol Hypertens,2007,16(3):204-12.
5Zhou X J,Silva F G.Membranoproliferative glomerulonephritis//[M] Jennette J C,Olson J L,Schwartz M M,et al ed.Heptinstall's Pathology of the Kidney[M].Philadelphia:Lippincott Williams & Wilkins,2007:253-19.
6Hovind P,Rossing P,Tarnow L,et al.Progression of diabetic nephropathy[J].Kidney Int,2001,59(2):702-9.
8Kanauchi M,Kawano T,Dohi K.Serum IgA levels in patients with diabetic nephropathy and IgA nephropathy superimposed on diabetes mellitus[J].Diab Res Clin Pract,2000,48(2):113-8.
9周庚寅.肾脏病理诊断图谱[M].北京:北京大学出版社,2007:144-214.
10Schwartz M M,Korbet S M,Lewis E J.Immunotactoid glomerulopathy[J].J Am Soc Nephrol,2002,13(5):1390-7.
3Walker PD, Ferrario F, Joh K, et al. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol, 2007, 20 (6) :605 -616.
4Licht C, Heinen S, Jozsi M, et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease ( MPGN Ⅱ ). Kidney Int, 2006,70( 1 ) :42 -50.
5Smith RJ, Alexander J, Barlow PN,et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol, 2007,18(9) : 2447 - 2456.
6Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type Ⅱ ( dense deposit disease) : an update. J Am Soc Nephrol, 2005,16 (5) : 1392 - 1403.
8Tibbs ME, Andreoli SP, Phillips CL. Membranoproliferative glomerulonephfitis type Ⅱ in a 10-year-old girl. Clin Lab Sci, 2005,18 (2) :84 -89.
9Aita K, Ito S, Tanabe K, et al. Early recurrence of dense deposit disease with marked endocapillary proliferation after renal transplantation. Pathol Int, 2006,56(2):101 -109.
10Bennett WM, Fassett RG, Walker RG, et al. Mesangiocapillary glomerulonephritis type Ⅱ (dense-deposit disease) : clinical features of progressive disease. Am J Kidney Dis, 1989,13(6) :469 -476.
1Beck L H Jr, Salant D J. Membranous nephropathy: recent travels and new roads ahead[J]. Kidney Int, 2010,77(9) :765 -70.
2Dryer S E, Reiser J. TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology[ J]. Am J Physiol Renal Physiol, 2010,299(4) :689 -701.
3Nielsen J S, McNagny K M. The role of podocalyxin in health and disease [ J ]. J Am Soc Nephrol, 2009,20 ( 8 ) : 1669 - 76.
4Thomas M C. Pathogenesis and progression of proteinurla [ J ]. Contrib Nephrol, 2011,170:48 - 56.
5Haraldsson B, NystrSm J, Deen W M. Properties of the glomerular barrier and mechanism of proteinuria [ J ]. Physiol Rev, 2008,88 (2) :451 -87.
6Reiser J, Polu K R, Mfiller C C, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function [ J ]. Nature Genetics, 2005,37 (7) :739 - 44.
7Mukerji N, Damodaran T V, Winn M P. TRPC6 and FSGS : the latest TRP channelopathy[ J]. Biochim Biophys Acta, 2007,1772 (8) :859 -68.
8Mfiller C C, Flesche J, Reiser J. Sensitizing the slit diaphragm with TRPC6 ion channels [ J ]. J Am Soc Nephml, 2009,20 (5) : 950 - 3.
9Kavoura E, Gakiopoulou H, Paraskevakou H, et al. Immunohisto- chemical evaluation of podocalyxin expression in glomerulopathies associated with nephrotic syndrome [ J]. Hum Pathol, 2011,42 (2) :227 -35.
